Posted on December 3, 2018
The new version of InSyBio Suite has a significant increase in speed and refinement of the predictive biomarkers process.
InSyBio Suite version 2.4 has been officially launched on Monday 26th of November 2018. The Chief Scientific Officer of InSyBio, Dr. Seferina Mavroudi, stated that "At InSyBio we are crazy enough to think that we can revolutionize the biomarker discovery process – and maybe we have".
InSyBio Biomarkers tool offers the following key features:
Other important updates include:
The CEO of InSyBio, Labros Digonis, stated that "Big data—and, more importantly, its effective analysis—enable an unprecedented understanding of the world around us, and make it possible to improve Pharmaceutical and Food/Nutrition Industries to work more effectively and efficiently. Knowing the great added value the Suite brings on, we believe the Insybio Suite will be established as the analysis platform of choice, ‘the SAP’ for Pharma and Nutrition Industries’ R&D".
About InSyBio: InSyBio is an international bioinformatics pioneer company in precision medicine and nutrition, which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data.
Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research goals (such as robust biomarker discovery and accurate predictive models). Since 2013, InSyBio has worked with hundreds of academics, companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an average increase of 10% in predictive accuracy and decrease of at least 80% in overall time and cost.
Visit www.insybio.com to see how InSyBio can help you reach your R&D goals in the era of Precision Medicine and Nutrition.
InSyBio participates in the NBG Business Seeds and the International Accelerator Programs.
For any further detail contact our Business Development Manager, Mackenzie Hastings, at email@example.com .
For more News visit our InSyBio Blog.